$7.70
Value $118M
Atara BiotherapeuticsvsThermo Fisher Scientific
ATRA and TMO stock compared: price, dividend, valuation and results, from SEC filings.
-2.90%
$700.22
Value $260B
Atara Biotherapeutics (ATRA) has a market value of $118M and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, ATRA moved -38.3% and TMO +19.5%. Dividend yield: ATRA none, TMO 0.26%.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ATRA$118M
TMO$260B
TMO is 2,204 times ATRA
Revenue, 12 months
ATRA$4.0M
TMO$47.4B
TMO is 11,942 times ATRA
Net income, 12 months
ATRA-$15M
TMO$7.1B
Operating margin
ATRA-343.6%
TMO17.9%
361.5 points apart
ROIC
ATRA–
TMO8.2%
P/E
ATRA–
TMO36.8
Dividend yield
ATRA0.0%
TMO0.3%
0.3 points apart
5-year return
ATRA-98.3%
TMO+11.8%
110.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ATRA-98.2%
TMO+11.8%
| Period | ATRAWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | -38.3%Price -38.3% | +19.5%Price +19.1% |
| 3 years since November 13, 2023 | +19.8%+6.2% a yearPrice +19.8% | +58.8%+16.7% a yearPrice +57.3% |
| 5 years since November 12, 2021 | -98.3%-55.5% a yearPrice -98.3% | +11.8%+2.3% a yearPrice +10.2% |
| 10 years since November 15, 2016 | -98.4%-33.9% a yearPrice -98.4% | +384.5%+17.1% a yearPrice +371.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
ATRAAtara BiotherapeuticsTMOThermo Fisher Scientific
Valuation
ATRATMO| Price | $7.70 | $700.22 |
|---|---|---|
| Market value | $118M | $260B |
| Enterprise value (EV) | – | $295B |
| P/E | – | 36.8 |
| P/E, 5-year median | – | 32.7 |
| P/B | – | 4.8 |
| EV/EBIT | – | 34.9 |
| Free cash flow yield | – | 2.9% |
Results and growth
ATRATMO| Revenue, 12 months | $4.0M | $47.4B |
|---|---|---|
| Net income, 12 months | -$15M | $7.1B |
| Free cash flow, 12 months | -$13M | $7.6B |
| Earnings per share, 12 months | -$1.12 | $18.96 |
| Revenue growth, year on year | -6.3% | 3.9% |
| Revenue growth a year, past | +23.8%over 3 years | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
Margins and returns on capital
ATRATMO| Gross margin | – | – |
|---|---|---|
| Operating margin | -343.6% | 17.9% |
| Net margin | -368.6% | 14.9% |
| ROIC | – | 8.2% |
| ROE | – | 13.4% |
Balance sheet
ATRATMO| Cash | $9.9M | $6.1B |
|---|---|---|
| Total debt | – | $41.4B |
| Net debt / EBITDA | – | 3.7 |
| Interest cover | -4.8× | 5.5× |
Dividends and buybacks
ATRATMO| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, Atara Biotherapeutics or Thermo Fisher Scientific?
By market value, Thermo Fisher Scientific ($260B) is about 2,204.2 times Atara Biotherapeutics ($118M), at today's prices.
How did ATRA and TMO stock do over the last 10 years?
Since November 15, 2016, ATRA's price moved -98.4% and TMO's +371.0%. With dividends: ATRA -98.4% (-33.9% a year), TMO +384.5% (+17.1% a year). Past returns do not predict future ones.
Which pays the higher dividend, ATRA or TMO?
The dividend yield at today's price is none for Atara Biotherapeutics and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
Which has the higher profit margins, Atara Biotherapeutics or Thermo Fisher Scientific?
Over the last twelve months, the net margin was -368.6% for Atara Biotherapeutics and 14.9% for Thermo Fisher Scientific, and the operating margin -343.6% and 17.9%. Revenue was $4.0M and $47.4B.
Which is the better investment, Atara Biotherapeutics or Thermo Fisher Scientific?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.